We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+9.37%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$750M
AUM Growth
+$14.3M
Cap. Flow
+$13M
Cap. Flow %
1.73%
Top 10 Hldgs %
50.53%
Holding
71
New
20
Increased
16
Reduced
11
Closed
15

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$31.4M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$17.5M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15M
4
ROIV icon
Roivant Sciences
ROIV
+$13.6M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$12.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$28.5M
2
ACLX
Arcellx
ACLX
+$15.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$15.8M
4
RCUS icon
Arcus Biosciences
RCUS
+$15.2M
5
IMVT icon
Immunovant
IMVT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 93.46%
2 Miscellaneous 6.47%
3 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOBT
51
DELISTED
IO Biotech
IOBT
$696K 0.09%
+493,827
New +$868K
IMUX icon
52
Immunic
IMUX
$141M
$619K 0.08%
42,118
– –
CYPH
53
Cypherpunk Technologies Inc
CYPH
$331M
$489K 0.07%
+354,266
New +$824K
TYRA icon
54
Tyra Biosciences
TYRA
$1.68B
$439K 0.06%
31,872
– –
LIAN
55
DELISTED
LianBio American Depositary Shares
LIAN
$417K 0.06%
280,000
– –
NUVB.WS
56
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$6.67K ﹤0.01%
66,666
– –
ACLX
57
DELISTED
Arcellx
ACLX
– –
-500,000
Closed -$15.8M
ACRS icon
58
Aclaris Therapeutics
ACRS
$795M
– –
-525,000
Closed -$5.44M
BCYC
59
Bicycle Therapeutics
BCYC
$258M
– –
-520,000
Closed -$13.3M
BIIB icon
60
Biogen
BIIB
$32.4B
– –
-100,000
Closed -$28.5M
BMRN icon
61
BioMarin Pharmaceuticals
BMRN
$12.6B
– –
-100,000
Closed -$8.67M
COGT icon
62
Cogent Biosciences
COGT
$5.76B
– –
-800,000
Closed -$9.47M
DAWN
63
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-650,000
Closed -$7.76M
DBVT
64
DBV Technologies
DBVT
$786M
– –
-120,000
Closed -$2.28M
LKFT
65
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
– –
-250,000
Closed -$10.2M
KURA icon
66
Kura Oncology
KURA
$1.04B
– –
-500,000
Closed -$5.29M
MRSN
67
DELISTED
Mersana Therapeutics
MRSN
– –
-112,000
Closed -$9.21M
RCUS icon
68
Arcus Biosciences
RCUS
$3.25B
– –
-750,000
Closed -$15.2M
TNYA icon
69
Tenaya Therapeutics
TNYA
$151M
– –
-600,000
Closed -$3.52M
VIR icon
70
Vir Biotechnology
VIR
$1.85B
– –
-200,000
Closed -$4.91M
MRNS
71
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-525,000
Closed -$5.7M
1 2
3

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q3 2023 Portfolio in Review

As of Q3 2023, Logos Global Management held 71 positions worth $750M, up 1.9% from $735M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Logos Global Management's Q3 2023 filing shows 20 new, 16 increased, 11 reduced and 15 closed positions. Its largest new stake was Cerevel Therapeutics Holdings, Inc. Common Stock: 700,000 shares worth $15.3M. The largest sale was Biogen, an estimated $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.

  • Logos Global Management's largest Q3 2023 buy was Cerevel Therapeutics Holdings, Inc. Common Stock: 700,000 shares worth $15.3M.
  • Logos Global Management added most to Rocket Pharmaceuticals in Q3 2023, an estimated $31.4M increase.
  • Logos Global Management's biggest Q3 2023 reduction was Neurocrine Biosciences, cutting an estimated $15.8M.
  • Logos Global Management fully exited Biogen in Q3 2023, selling an estimated $28.5M.
  • Logos Global Management's ten largest holdings make up 51% of its $750M portfolio in Q3 2023.
  • Logos Global Management opened 20 new positions and closed 15 in Q3 2023.
  • Logos Global Management's portfolio value rose 1.9% quarter-over-quarter to $750M.

Based on Logos Global Management's 13F filing for Q3 2023, filed 14 Nov 2023.